Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
I say aortic root dilation management because I am not yet ready for any type of surgical therapy for my aortic root dilation aka my aortic root slowly growing. According to echocardiograms, my aortic root bounces around from 5.3 cm to 4.9, 5.0, and was 5.1 for the most recent echo.
When I say “I’m not ready” I want to be direct and explain that I am a long-term myeloma survivor who had a terrible experience with conventional oncology. As a result, I have been managing all of my long-term side effects, including my chemotherapy-induced cardiomyopathy, with evidence-based non-conventional therapies.
Aortic root surgery has risks. Walking around with an moderately enlarged Ao Root also has risks. I’m trying to balance those risks and decide when and how best to treat my Aortic Root Dilation.
Marfan’s Syndrome runs in my family. While I have never been diagnosed I’m assuming that Marfan’s is influencing my heart health. I don’t think aggressive cardiotoxic chemotherapy helped my heart health either but I’ll never know.
At this point in my long-term survivor care, I rely on heart-healthy nutrition and nutritional supplementation. As well as heart-healthy lifestyle therapies such as moderate exercise.
What do you think of my aortic root dilation management? If you have any experience in this area I would appreciate your input.
Thanks in advance,
“Abstract- Aortic root dilation (AoD) imparts increased risk of aortic complications such as dissection, rupture, and valvular regurgitation. Multiple etiologies of AoD exist, such as Marfan syndrome, bicuspid aortic valve, Ehler-Danlos syndrome, infections, and idiopathic conditions. Due to the variety of clinical conditions that can result in AoD, and the risks associated with worsening AoD, a thorough understanding of the pathophysiology of AoD, noninvasive imaging modalities, and pharmacologic therapies is critical…
The anatomy of the aortic root includes the
with the size being a function of a patient’s biologic variables such as height, age, BSA, and gender [1, 2]. However, while natural variations in the size of the aortic root are well known, the identification of progression from normal to pathologic AoD is a key clinical diagnosis that carries significant cardiovascular risk including aortic dissection, rupture, valvular regurgitation and cardiac tamponade [1, 3, 4, 5]…
MFS is one of the most common hereditary disorders of connective tissues and is characterized by manifestations in cardiovascular, skeletal, and ocular systems [7]. MFS is the most common genetic cause of thoracic aortic aneurysms (TAAs). Its inheritance is almost exclusively autosomal dominant and mostly involves a mutation of the fibrillin-1 (FBN1) gene encoding the connective tissue structural protein fibrillin-1 [8]. The widely accepted incidence of Marfan syndrome is ~1 in 5000 individuals [9]…
Abstract- Surgery of the aortic root is a challenging operation for which different techniques have been developed and refined over the last five decades. We present a review of surgical strategies and their most relevant modifications along with a summary of the most recent evidence on early and long-term outcomes.
Additionally, we provide brief descriptions of the use of the valve-sparing technique in various clinical settings, including high-risk patients such as those with connective tissue disorders or concomitant dissection…
More recently, the use of VSRR has expanded to higher risk cohorts, such as those with severe AI, reoperations or type A dissections. Propensity-matched analyses have offered additional insight. In our analysis of 890 consecutive aortic root replacement procedures, we found zero in-hospital or early mortality in patients undergoing VSRR, with an overall operative mortality of 0.2% and an incidence of major postoperative complications of 0.5% (8).
Surgical technique (mCVG vs. bCVG vs. VSRR) did not affect in-hospital mortality or long-term survival. In a more recent review of VSRR, we again found zero in-hospital or early mortality in patients undergoing VSRR (11)…
VSRR has been studied extensively in patients with Marfan syndrome and other connective tissue disorders and has been found to be a safe alternative to valve-replacing aortic root surgery. As many of these patients are in the younger age spectrum, the ability to preserve the native aortic valve has clear potential benefit compared to replacement with a mechanical or bioprosthetic valve-conduit. Coselli et al. found in a multicenter study that VSRR had a higher cumulative incidence of adverse valve-related events, although this finding was driven mostly by valve dysfunction and AI…”
Conclusions- The natural histories of the aortic root and mid‐ascending aorta are uniquely different. Dilation of the aortic root imparts a significant higher risk of adverse events. A diameter shift for intervention to 5.0 cm for the aortic root and to 5.25 cm for the mid‐ascending aorta should be considered at expert centers…”